11 March 2024
11 March 2024
Lilly’s lebrikizumab showed improvement in at least 75% of patients with darker skin tones with atopic dermatitis in the Phase III trial.
In the trial, 100mg twice-daily dose of JNJ-2113 showed the highest Psoriasis Area and Severity Index 75 response rates.
The pilot study will examine the company’s N-tidal device with 75 children under five years old with asthma and viral wheezing.
The trial will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of ARO-DM1 in DM1 patients.
PT-112 is being evaluated for its safety and efficacy in people with late-stage mCRPC in the trial.
The company anticipates reporting topline data for this Phase II trial in the second half of this year.
According to KOLs, Ozempic could be an excellent option for patients who are both diabetic and obese.
The US joins more than 100 countries where the contraceptive pill is available without a prescription.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
